{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:34:43Z","timestamp":1769524483778,"version":"3.49.0"},"reference-count":84,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Center of Sciences","award":["NCN 2014\/13\/D\/NZ7\/00322"],"award-info":[{"award-number":["NCN 2014\/13\/D\/NZ7\/00322"]}]},{"name":"National Center of Sciences","award":["2013\/09\/B\/NZ7\/00423"],"award-info":[{"award-number":["2013\/09\/B\/NZ7\/00423"]}]},{"name":"NCBiR","award":["ORGANOMET No: PBS2\/A5\/40\/2014"],"award-info":[{"award-number":["ORGANOMET No: PBS2\/A5\/40\/2014"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188767","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T14:41:15Z","timestamp":1523630475000},"page":"e0188767","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Piperazinyl fragment improves anticancer activity of Triapine"],"prefix":"10.1371","volume":"13","author":[{"given":"Marta","family":"Rejmund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mrozek-Wilczkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Malarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Pyrkosz-Bulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Gajcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieczyslaw","family":"Sajewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Musiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-6562","authenticated-orcid":true,"given":"Jaroslaw","family":"Polanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"ref1","first-page":"1","article-title":"Structural and physical correlations in the biological properties of transition metal heterocyclic thiosemicarbazone and S-alkyldithiocarbazate complexes","author":"DX West","year":"1991","journal-title":"Complex Chemistry"},{"key":"ref2","first-page":"167","article-title":"Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone","volume":"16","author":"RW Brockman","year":"1956","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10637-007-9085-0","article-title":"A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells","volume":"26","author":"B Ma","year":"2008","journal-title":"Invest New Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"55848","DOI":"10.1039\/C6RA07659A","article-title":"Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity","volume":"6","author":"B Fischer","year":"2016","journal-title":"RSC Adv"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00280-002-0480-0","article-title":"Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule","volume":"50","author":"L Feun","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10637-007-9066-3","article-title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium","volume":"25","author":"MJ Mackenzie","year":"2007","journal-title":"Invest New Drugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00280-011-1779-5","article-title":"A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study","volume":"69","author":"J Chao","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-008-9115-6","article-title":"Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia","volume":"26","author":"OM Odenike","year":"2008","journal-title":"Invest New Drugs"},{"key":"ref9","first-page":"331","article-title":"A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer","volume":"54","author":"Y Yen","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1021\/jm00098a012","article-title":"Synthesis and Antitumor Activity of Amino Derivatives of Pyridine-2-carboxaldehyde Thiosemicarbazone","volume":"35","author":"MC Liu","year":"1992","journal-title":"J Med Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0145-2126(03)00118-8","article-title":"Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia","volume":"27","author":"FJ Giles","year":"2003","journal-title":"Leuk Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-008-9123-6","article-title":"A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas","volume":"26","author":"S Attia","year":"2008","journal-title":"Invest New Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10637-007-9044-9","article-title":"Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)","volume":"25","author":"JJ Knox","year":"2007","journal-title":"Invest New Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1021\/jm900528d","article-title":"Impact of metal coordination on cytotoxicity of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (Triapine) and novel insights into terminal dimethylation","volume":"52","author":"CR Kowol","year":"2009","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1021\/jm000979z","article-title":"Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of (4)N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines","volume":"44","author":"J Easmon","year":"2001","journal-title":"J Med Chem"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","article-title":"Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors","volume":"52","author":"Y Yu","year":"2009","journal-title":"J Med Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"35768","DOI":"10.1074\/jbc.M112.396911","article-title":"Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: Tyrosyl radical quenching not involving reactive oxygen species","volume":"287","author":"Y Aye","year":"2012","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbagen.2011.11.007","article-title":"Iron mobilization from transferrin by therapeutic iron chelating agents","volume":"1820","author":"RW Evans","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0006-291X(83)91040-9","article-title":"Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism","volume":"110","author":"L Thelander","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"D Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e110291","DOI":"10.1371\/journal.pone.0110291","article-title":"Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships","volume":"9","author":"M Serda","year":"2014","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.bmcl.2006.01.048","article-title":"Synthesis and anticancer activity of thiosemicarbazones","volume":"16","author":"W Hu","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jinorgbio.2009.12.021","article-title":"Zinc(II) complexes of 2-acetyl pyridine 1-(4-fluorophenyl)-piperazinyl thiosemicarbazone: Synthesis, spectroscopic study and crystal structures\u2014potential anticancer drugs","volume":"104","author":"TP Stanojkovic","year":"2010","journal-title":"J Inorg Biochem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejmech.2011.11.022","article-title":"New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds","volume":"47","author":"J Faist","year":"2012","journal-title":"Eur J Med Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.bmcl.2004.12.028","article-title":"Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent","volume":"15","author":"T Ochi","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.clinthera.2007.09.015","article-title":"Posaconazole: an extended-spectrum triazole antifungal agent","volume":"29","author":"DS Schiller","year":"2007","journal-title":"Clin Ther"},{"key":"ref27","unstructured":"Ae N, Fujiwara Y. Process of a quaternary ammonium salt. US20110263847A1, 2011."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13543776.2016.1189902","article-title":"Piperazine derivatives for therapeutic use: a patent review (2010-present)","volume":"26","author":"AK Rathi","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.1039\/c1dt10870k","article-title":"Interaction of Zn(II) with quinolone drugs: structure and biological evaluation","volume":"40","author":"A Tarushi","year":"2011","journal-title":"Dalton Trans"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1021\/ic101378s","article-title":"Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies","volume":"49","author":"V Kub\u00edcek","year":"2010","journal-title":"Inorg Chem"},{"key":"ref31","first-page":"217","article-title":"Chemoinformatics approaches to virtual screening","author":"E Proschak","year":"2008"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","article-title":"Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo","volume":"55","author":"DB Lovejoy","year":"2012","journal-title":"J Med Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1021\/jm0606342","article-title":"Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity","volume":"49","author":"DR Richardson","year":"2006","journal-title":"J Med Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","article-title":"Novel di-2-pyridyl\u2013derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment","volume":"104","author":"J Yuan","year":"2004","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bjp.0705089","article-title":"Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents","volume":"138","author":"EM Becker","year":"2003","journal-title":"Br J Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1021\/jm101340q","article-title":"Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent","volume":"54","author":"Y Wang","year":"2011","journal-title":"J Med Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1016\/j.bmcl.2016.10.007","article-title":"Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR\u2013ABL kinase inhibitors","volume":"26","author":"L Hu","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.bmcl.2006.05.085","article-title":"Dithiocarbamic acid esters as anticancer agent. Part 1: 4-Substituted-piperazine-1-carbodithioic acid 3-cyano-3,3-diphenyl-propyl esters","volume":"16","author":"X Hou","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin","volume":"69","author":"K Yu","year":"2009","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1124\/mol.63.6.1382","article-title":"DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS","volume":"63","author":"H Gao","year":"2003","journal-title":"Mol Pharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1016\/j.bmcl.2012.07.030","article-title":"Synthesis and Characterization of Quinoline-Based Thiosemicarbazones and Correlation of Cellular Iron-Binding Efficacy to Anti-Tumor Efficacy","volume":"22","author":"M Serda","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/ml400422a","article-title":"Iron Chelators in Photodynamic Therapy Revisited: Synergistic Effect by Novel Highly Active Thiosemicarbazones","volume":"5","author":"A Mrozek-Wilczkiewicz","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/ci00053a005","article-title":"Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions","volume":"27","author":"AK Ghose","year":"1987","journal-title":"J Chem Inf Comput Sci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"DS Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/ejic.200901174","article-title":"Comparative Solution Equilibrium Study of the Interactions of Copper(II), Iron(II) and Zinc(II) with Triapine (3-Aminopyridine-2-carbaldehyde Thiosemicarbazone) and Related Ligands","volume":"2010","author":"\u00c9A Enyedy","year":"2010","journal-title":"Eur J Inorg Chem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1002\/ejic.201200360","article-title":"Complex-Formation Ability of Salicylaldehyde Thiosemicarbazone towards Zn II, Cu II, Fe II, Fe III and Ga III Ions","volume":"2012","author":"\u00c9A Enyedy","year":"2012","journal-title":"Eur J Inorg Chem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"9071","DOI":"10.1039\/C5DT01076D","article-title":"Strong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-piperazine and thiosemicarbazone-morpholine hybrids","volume":"44","author":"F Bacher","year":"2015","journal-title":"Dalt Trans"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.2042-7158.1981.tb13735.x","article-title":"Effect of pH on the micellar properties of amphiphilic drugs in aqueous solution","volume":"33","author":"D Attwood","year":"1981","journal-title":"J Pharm Pharmacol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.bmc.2008.12.015","article-title":"Determination of 1-aryl-4-propylpiperazine pKa values: The substituent on aryl modulates basicity","volume":"17","author":"E Lacivita","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0003-2670(01)83033-6","article-title":"Acid\u2014base equilibria of some benzhydryl piperazine derivatives","volume":"86","author":"M Smyth","year":"1976","journal-title":"Anal Chim Acta"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1039\/c0dt01835j","article-title":"Interaction of Triapine and related thiosemicarbazones with iron(III)\/(II) and gallium(III): a comparative solution equilibrium study","volume":"40","author":"\u00c9A Enyedy","year":"2011","journal-title":"Dalton Trans"},{"key":"ref52","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-009-5883-8","article-title":"pK a Prediction for Organic Acids and Bases","author":"DD Perrin","year":"1981"},{"key":"ref53","article-title":"Chemistry of Complex Equilibria","author":"MT Beck","year":"1990"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0020-1693(00)80471-5","article-title":"Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. Ionisation characteristics of the ligands and their relevance to biological properties","volume":"170","author":"DR Richardson","year":"1990","journal-title":"Inorganica Chim Acta"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejmech.2014.05.001","article-title":"Design and synthesis of novel 5,6-disubstituted pyridine-2,3-dione-3-thiosemicarbazone derivatives as potential anticancer agents","volume":"81","author":"W Xie","year":"2014","journal-title":"Eur J Med Chem"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"13483","DOI":"10.3390\/molecules171113483","article-title":"Investigation of the Biological Properties of (Hetero)Aromatic Thiosemicarbazones","volume":"17","author":"M Serda","year":"2012","journal-title":"Molecules"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.molstruc.2012.11.050","article-title":"Microwave assisted synthesis, X-ray crystallography and DFT calculations of selected aromatic thiosemicarbazones","volume":"1037","author":"M Serda","year":"2013","journal-title":"J Mol Struct"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"42411","DOI":"10.18632\/oncotarget.6389","article-title":"Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents","volume":"6","author":"V Sestak","year":"2015","journal-title":"Oncotarget"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0304-3835(92)90239-R","article-title":"Influence of dietary iron overload on cell proliferation and intestinal tumorigenesis in mice","volume":"65","author":"CP Siegers","year":"1992","journal-title":"Cancer Lett"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.10348","article-title":"Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity","volume":"73","author":"TB Chaston","year":"2003","journal-title":"Am J Hematol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3892\/ijo.2013.2063","article-title":"Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin","volume":"43","author":"VF Chekhun","year":"2013","journal-title":"Int J Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1158\/0008-5472.CAN-11-1870","article-title":"An iron regulatory gene signature predicts outcome in breast cancer","volume":"71","author":"LD Miller","year":"2011","journal-title":"Cancer Res"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1615\/CritRevOncog.2013007784","article-title":"Cellular iron metabolism in prognosis and therapy of breast cancer","volume":"18","author":"S V Torti","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"43ra56","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and iron regulation in breast cancer progression and prognosis","volume":"2","author":"ZK Pinnix","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"A Omuro","year":"2013","journal-title":"JAMA"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"DN Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.tem.2015.03.008","article-title":"Iron metabolism: A double-edged sword in the resistance of glioblastoma to therapies","volume":"26","author":"C Legendre","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12885-016-2074-y","article-title":"Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells","volume":"16","author":"C Legendre","year":"2016","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"ref69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-2362.2002.0320s1061.x","article-title":"Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation","volume":"32","author":"PH Gosselaar","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"ref70","first-page":"1","article-title":"The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo","volume":"17","author":"JC Lee","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation","volume":"104","author":"NTV Le","year":"2004","journal-title":"Blood"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.celrep.2014.02.042","article-title":"Iron metabolism regulates p53 signaling through direct Heme-p53 interaction and modulation of p53 localization, stability, and function","volume":"7","author":"J Shen","year":"2014","journal-title":"Cell Rep"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0304-419X(02)00068-9","article-title":"The role of iron in cell cycle progression and the proliferation of neoplastic cells","volume":"1603","author":"N Le","year":"2002","journal-title":"Biochim Biophys Acta\u2014Rev Cancer"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.4161\/cc.6.16.4603","article-title":"Tuning cell cycle regulation with an iron key","volume":"6","author":"Y Yu","year":"2007","journal-title":"Cell Cycle"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/emboj\/18.6.1571","article-title":"The p21(Cip1) and p27(Kip1) CDK \u201cinhibitors\u201d are essential activators of cyclin D-dependent kinases in murine fibroblasts","volume":"18","author":"M Cheng","year":"1999","journal-title":"EMBO J"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1476-5381.2011.01526.x","article-title":"Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy","volume":"165","author":"Y Yu","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy","volume":"80","author":"Z Kovacevic","year":"2011","journal-title":"Mol Pharmacol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"a008656","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase Functions in Cell Death and Disease","volume":"5","author":"DR McIlwain","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"S Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/sj.onc.1204815","article-title":"Apoptosis in the absence of caspase 3","volume":"20","author":"Y Liang","year":"2001","journal-title":"Oncogene"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/89.14.1036","article-title":"Characterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis","volume":"89","author":"C Gomez-Manzano","year":"1997","journal-title":"JNCI J Natl Cancer Inst"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/nar\/gkn1085","article-title":"Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences","volume":"37","author":"M Br\u00e1zdov\u00e1","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"ref83","unstructured":"Gans P, Sabatini A, Vacca A. Hypspec 2000. Leeds UK, Florence Italy;"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0010-8545(98)00260-4","article-title":"Hyperquad simulation and speciation (HySS): a utility program for the investigation of equilibria involving soluble and partially soluble species","volume":"184","author":"L Alderighi","year":"1999","journal-title":"Coord Chem Rev"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T01:56:57Z","timestamp":1540259817000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188767"}},"subtitle":[],"editor":[{"given":"Swati","family":"Palit Deb","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":84,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188767","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]}}}